Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07645222
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCHansoh BioMedical R&D CompanyNot Yet RecruitingPhase 1
NCT07645222Not Yet Recruiting
Phase 1
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCHansoh BioMedical R&D Com...
NCT07643987
Diagnosis of Gestational Diabetes Based on a 50-gram Glucose ChallengeMethodist Health SystemCompleted
NCT07643987Completed
—
Diagnosis of Gestational Diabetes Based on a 50-gram Glucose ChallengeMethodist Health System
NCT07645508
Comparison of Conventional, Patient-Specific, and Augmented Reality Navigation in Reverse Total Shoulder ArthroplastyKrankenhaus Barmherzige Schwestern LinzActive Not Recruiting
NCT07645508Active Not Recruiting
—
Comparison of Conventional, Patient-Specific, and Augmented Reality Navigation i...Krankenhaus Barmherzige S...
NCT07645690
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell CarcinomaChinese PLA General HospitalRecruitingEarly Phase 1
NCT07645690Recruiting
Early Phase 1
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Meta...Chinese PLA General Hospi...
NCT07644728
Sleep Quality and Biomarkers in Adolescent Girls With Anorexia NervosaUniversity Hospital of SplitNot Yet Recruiting
NCT07644728Not Yet Recruiting
—
Sleep Quality and Biomarkers in Adolescent Girls With Anorexia NervosaUniversity Hospital of Sp...
NCT07646015
Validate Smart Breath Analyzer as Screening Tool for Diabetic, Hepatic, Renal, Lung, and Other Metabolic DisordersJSS Medical College HospitalCompleted
NCT07646015Completed
—
Validate Smart Breath Analyzer as Screening Tool for Diabetic, Hepatic, Renal, L...JSS Medical College Hospi...
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07646236
Gamification Versus E-Learning for Electrocardiogram EducationTaiwan Municipal An-Nan Hospital-China Medical UniversityCompletedNot Applicable
NCT07646236Completed
Not Applicable
Gamification Versus E-Learning for Electrocardiogram EducationTaiwan Municipal An-Nan H...
NCT07644130
Bergen Four-Day Treatment (B4DT) for Obsessive-Compulsive DisorderTampere UniversityNot Yet RecruitingNot Applicable
NCT07644130Not Yet Recruiting
Not Applicable
Bergen Four-Day Treatment (B4DT) for Obsessive-Compulsive DisorderTampere University
NCT07644052
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use DisorderPleoPharma, Inc.RecruitingPhase 3
NCT07644052Recruiting
Phase 3
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cann...PleoPharma, Inc.
NCT07643831
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast CancerGenentech, Inc.Unknown
NCT07643831Unknown
—
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2-...Genentech, Inc.
NCT07644754
Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory MetastasesLudwig-Maximilians - University of MunichNot Yet RecruitingNot Applicable
NCT07644754Not Yet Recruiting
Not Applicable
Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level...Ludwig-Maximilians - Univ...
NCT07646223
Vancomycin Efficacy in Response to Dysbiosis in Atypical ColitisFimlab laboratoriesNot Yet RecruitingPhase 2
NCT07646223Not Yet Recruiting
Phase 2
Vancomycin Efficacy in Response to Dysbiosis in Atypical ColitisFimlab laboratories
NCT07644767
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar DepressionNeurocentrx Pharma Pty LtdNot Yet RecruitingPhase 2
NCT07644767Not Yet Recruiting
Phase 2
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar DepressionNeurocentrx Pharma Pty Lt...
NCT07643779
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflux DiseaseKarabuk UniversityNot Yet Recruiting
NCT07643779Not Yet Recruiting
—
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflu...Karabuk University
NCT07645404
The Effect of Mental Fatigue on Upper Extremity Functional PerformanceIzmir Bakircay UniversityNot Yet RecruitingNot Applicable
NCT07645404Not Yet Recruiting
Not Applicable
The Effect of Mental Fatigue on Upper Extremity Functional PerformanceIzmir Bakircay University
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07643805
Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCLThe First Affiliated Hospital with Nanjing Medical UniversityNot Yet RecruitingPhase 1
NCT07643805Not Yet Recruiting
Phase 1
Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Pat...The First Affiliated Hosp...
NCT07644026
HBV Reactivation Prediction Model in Allo-HSCTInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet Recruiting
NCT07644026Not Yet Recruiting
—
HBV Reactivation Prediction Model in Allo-HSCTInstitute of Hematology &...
NCT07644390
Development of a Dynamic Prediction Model for Crohn's Disease-Related Intestinal Surgery Using Longitudinal Indices of Routine Blood Tests: A Single-Center Retrospective Cohort StudySixth Affiliated Hospital, Sun Yat-sen UniversityCompleted
NCT07644390Completed
—
Development of a Dynamic Prediction Model for Crohn's Disease-Related Intestinal...Sixth Affiliated Hospital...
Result Breakdown
Not yet recruiting11 (55%)
Completed4 (20%)
Recruiting3 (15%)
Active, not recruiting1 (5%)
Unknown1 (5%)
Not Specified8 (40%)
not_applicable4 (20%)
Phase 13 (15%)
Phase 23 (15%)
Early Phase 11 (5%)
Phase 31 (5%)